Evaluation of the efficacy, safety and injection interval of intravitreal injection of aflibercept for central retinal vein occlusion

Trial Profile

Evaluation of the efficacy, safety and injection interval of intravitreal injection of aflibercept for central retinal vein occlusion

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Central retinal vein occlusion
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top